Literature DB >> 33420395

Impact of access to care on 1-year mortality following allogeneic blood or marrow transplantation.

Omer Jamy1, Alice Chen2, Kevin Battles2, Liton Francisco2, Donna Salzman3, Susan Bal3, Antonio Di Stasi3, Luciano Costa3, Ravi Bhatia3, Smita Bhatia2.   

Abstract

Mortality is highest in the first year following an allogeneic hematopoietic stem cell transplant. With recent advancements, we have expanded the pool of patients to whom we are able to offer transplant as a treatment option. In this context, we analyzed socioeconomic, patient, disease and transplant-related variables that predicted for 1-year all-cause, relapse-related (RRM) and non-relapse related mortality (NRM) in 304 patients at the University of Alabama at Birmingham. The 1-year overall survival, RRM and NRM rates were 60.5%, 13.5% and 22.7% respectively. A KPS score < 80, pre-transplant infection and hypertension and non-complete remission disease status adversely effected all-cause mortality. For NRM, increasing age, pre-transplant infection and diabetes, and poor access to care were associated with higher mortality whereas haploidentical donor type was associated with improved survival. For RRM, a KPS score <80, high/very high disease risk index and the presence of comorbidities were risk factors for higher mortality. Poor access to care, in addition to individual comorbidities, performance status and high-risk disease characteristics, is associated with adverse outcomes following transplant. We propose the incorporation of socioeconomic variables with patient, disease, and transplant-related variables to predict 1-year NRM.

Entities:  

Mesh:

Year:  2021        PMID: 33420395     DOI: 10.1038/s41409-020-01184-8

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN: 0268-3369            Impact factor:   5.174


  14 in total

1.  2013 AHA/ACC/TOS guideline for the management of overweight and obesity in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and The Obesity Society.

Authors:  Michael D Jensen; Donna H Ryan; Caroline M Apovian; Jamy D Ard; Anthony G Comuzzie; Karen A Donato; Frank B Hu; Van S Hubbard; John M Jakicic; Robert F Kushner; Catherine M Loria; Barbara E Millen; Cathy A Nonas; F Xavier Pi-Sunyer; June Stevens; Victor J Stevens; Thomas A Wadden; Bruce M Wolfe; Susan Z Yanovski; Harmon S Jordan; Karima A Kendall; Linda J Lux; Roycelynn Mentor-Marcel; Laura C Morgan; Michael G Trisolini; Janusz Wnek; Jeffrey L Anderson; Jonathan L Halperin; Nancy M Albert; Biykem Bozkurt; Ralph G Brindis; Lesley H Curtis; David DeMets; Judith S Hochman; Richard J Kovacs; E Magnus Ohman; Susan J Pressler; Frank W Sellke; Win-Kuang Shen; Sidney C Smith; Gordon F Tomaselli
Journal:  Circulation       Date:  2013-11-12       Impact factor: 29.690

2.  The impact of individual comorbidities on non-relapse mortality following allogeneic hematopoietic stem cell transplantation.

Authors:  Joshua A Fein; Avichai Shimoni; Myriam Labopin; Noga Shem-Tov; Ronit Yerushalmi; Hila Magen; Nadav Furie; Eli Kopel; Ivetta Danylesko; Arnon Nagler; Roni Shouval
Journal:  Leukemia       Date:  2018-06-27       Impact factor: 11.528

3.  Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT.

Authors:  Mohamed L Sorror; Michael B Maris; Rainer Storb; Frederic Baron; Brenda M Sandmaier; David G Maloney; Barry Storer
Journal:  Blood       Date:  2005-06-30       Impact factor: 22.113

4.  Impact of comorbidities constituting the hematopoietic cell transplant (HCT)-comorbidity index on the outcome of patients undergoing allogeneic HCT for acute myeloid leukemia.

Authors:  Manar M I Khalil; Jeffrey H Lipton; Eshetu G Atenafu; Vikas Gupta; Dennis D Kim; John Kuruvilla; Auro Viswabandya; Hans A Messner; Fotios V Michelis
Journal:  Eur J Haematol       Date:  2017-12-13       Impact factor: 2.997

5.  Clinical Impact of Pretransplant Multidrug-Resistant Gram-Negative Colonization in Autologous and Allogeneic Hematopoietic Stem Cell Transplantation.

Authors:  Alessandra Forcina; Francesca Lorentino; Vincenzo Marasco; Chiara Oltolini; Magda Marcatti; Raffaella Greco; Maria Teresa Lupo-Stanghellini; Matteo Carrabba; Massimo Bernardi; Jacopo Peccatori; Consuelo Corti; Fabio Ciceri
Journal:  Biol Blood Marrow Transplant       Date:  2018-03-02       Impact factor: 5.742

6.  Outcomes in patients age 70 or older undergoing allogeneic hematopoietic stem cell transplantation for hematologic malignancies.

Authors:  Andrew M Brunner; Haesook T Kim; Erin Coughlin; Edwin P Alyea; Philippe Armand; Karen K Ballen; Corey Cutler; Bimalangshu R Dey; Brett Glotzbecker; John Koreth; Steven L McAfee; Thomas R Spitzer; Robert J Soiffer; Joseph H Antin; Vincent T Ho; Yi-Bin Chen
Journal:  Biol Blood Marrow Transplant       Date:  2013-06-18       Impact factor: 5.742

7.  Donor compatibility and performance status affect outcome of allogeneic haematopoietic stem cell transplant in patients with relapsed or refractory acute myeloid leukaemia.

Authors:  Daniela Damiani; Mario Tiribelli; Antonella Geromin; Michela Cerno; Alessandra Sperotto; Eleonora Toffoletti; Erica Simeone; Angela Michelutti; Margherita Cavallin; Renato Fanin
Journal:  Ann Hematol       Date:  2012-08-15       Impact factor: 3.673

8.  Significant improvement in survival after unrelated donor hematopoietic cell transplantation in the recent era.

Authors:  Navneet S Majhail; Pintip Chitphakdithai; Brent Logan; Roberta King; Steven Devine; Susan N Rossmann; Gregory Hale; Robert J Hartzman; Chatchada Karanes; Ginna G Laport; Eneida Nemecek; Edward L Snyder; Galen E Switzer; John Miller; Willis Navarro; Dennis L Confer; John E Levine
Journal:  Biol Blood Marrow Transplant       Date:  2014-10-15       Impact factor: 5.742

9.  Reducing transplant-related mortality after allogeneic hematopoietic stem cell transplantation.

Authors:  Andrea Bacigalupo; Maria Pia Sormani; Teresa Lamparelli; Francesca Gualandi; Domenico Occhini; Stefania Bregante; Anna Maria Raiola; Carmen di Grazia; Alida Dominietto; Elisabetta Tedone; Giovanna Piaggio; Marina Podesta; Barbara Bruno; Rosi Oneto; Anna Lombardi; Francesco Frassoni; Davide Rolla; Gianandrea Rollandi; Claudio Viscoli; Carlo Ferro; Lucia Garbarino; Maria Teresa Van Lint
Journal:  Haematologica       Date:  2004-10       Impact factor: 9.941

10.  Hematopoietic cell transplantation-comorbidity index and Karnofsky performance status are independent predictors of morbidity and mortality after allogeneic nonmyeloablative hematopoietic cell transplantation.

Authors:  Mohamed Sorror; Barry Storer; Brenda M Sandmaier; David G Maloney; Thomas R Chauncey; Amelia Langston; Richard T Maziarz; Michael Pulsipher; Peter A McSweeney; Rainer Storb
Journal:  Cancer       Date:  2008-05-01       Impact factor: 6.860

View more
  2 in total

1.  Increasing access to allogeneic hematopoietic cell transplant: an international perspective.

Authors:  Vanderson Rocha; Giancarlo Fatobene; Dietger Niederwieser
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2021-12-10

2.  Impact of allogeneic stem cell transplantation comorbidity indexes after haplotransplant using post-transplant cyclophosphamide.

Authors:  Maxime Jullien; Corentin Orvain; Ana Berceanu; Marie-Anne Couturier; Thierry Guillaume; Pierre Peterlin; Alice Garnier; Amandine Le Bourgeois; Marion Klemencie; Aline Schmidt; Mathilde Hunault; Etienne Daguindau; Xavier Roussel; Pascal Delepine; Gaelle Guillerm; Aurelien Giltat; Sylvie François; Sylvain Thepot; Steven Le Gouill; Marie-C Béné; Patrice Chevallier
Journal:  Cancer Med       Date:  2021-09-21       Impact factor: 4.452

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.